Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
J Hepatol
    June 2024
  1. PATMORE LA, Sonneveld MJ
    Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
    J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
    >> Share

  2. SHAN D, Zhang G, Du Z
    Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
    J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
    >> Share

  3. LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
    Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
    J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
    >> Share

  4. LI M, Bhoori S, Mehta N, Mazzaferro V, et al
    Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
    >> Share

  5. COLAPIETRO F, Akpinar R, Pugliese N, Di Tommaso L, et al
    Unexpected diagnosis in females with abnormal liver ultrasound.
    J Hepatol. 2024;80:e243-e245.
    >> Share

  6. DUIJZER R, Boerrigter MM, Gevers TJG, Drenth JPH, et al
    The pathophysiology of polycystic liver disease.
    J Hepatol. 2024;80:981-983.
    >> Share

  7. BROUWERS MCGJ, Cassiman D
    Rare monogenic causes of steatotic liver disease masquerading as MASLD.
    J Hepatol. 2024;80:e252-e253.
    >> Share

  8. HASHIDA R, Nakano D, Kawaguchi M, Younossi ZM, et al
    Changing from NAFLD to MASLD: The implications for health-related quality of life data.
    J Hepatol. 2024;80:e249-e251.
    >> Share

  9. NORMAN JS, Mehta N
    Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    J Hepatol. 2024;80:e273-e274.
    >> Share

  10. DAI H, Zhu C, Huai Q, Xu W, et al
    Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
    J Hepatol. 2024;80:913-927.
    >> Share

  11. WU XN, Wang MZ, Zhang N, Zhang W, et al
    Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
    J Hepatol. 2024;80:928-940.
    >> Share

  12. ZOU Z, Liu X, Yu J, Ban T, et al
    Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    J Hepatol. 2024;80:834-845.
    >> Share

  13. CABIBBO G, Celsa C, Rimassa L, Torres F, et al
    Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice.
    J Hepatol. 2024;80:957-966.
    >> Share

  14. PANG Y, Aberg F, Chen Z, Li L, et al
    Predicting risk of chronic liver disease in Chinese adults: External validation of the CLivD score.
    J Hepatol. 2024;80:e264-e266.
    >> Share

  15. HE C, Lu D, Zheng S, Xu X, et al
    Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
    J Hepatol. 2024;80:e287-e288.
    >> Share

  16. ZHANG Y, Liu H, Sheng B, Tham YC, et al
    Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?
    J Hepatol. 2024;80:e279-e281.
    >> Share

  17. VARGHESE J, Chapiro J
    ChatGPT: The transformative influence of generative AI on science and healthcare.
    J Hepatol. 2024;80:977-980.
    >> Share

    May 2024
  18. LAO Y, Cui X, Xu Z, Yan H, et al
    Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
    J Hepatol. 2024 May 31:S0168-8278(24)00369-6. doi: 10.1016/j.jhep.2024.
    >> Share

  19. PATERNOSTRO R, Kwanten WJ, Hofer BS, Semmler G, et al
    Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.
    >> Share

  20. ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
    Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
    >> Share

  21. DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
    Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
    J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
    >> Share

  22. CHAPUS F, Giraud G, Huchon P, Roda M, et al
    Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
    J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
    >> Share

  23. CHEN J, Kaya NA, Zhang Y, Kendarsari RI, et al
    A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory.
    J Hepatol. 2024 May 21:S0168-8278(24)00352-0. doi: 10.1016/j.jhep.2024.
    >> Share

  24. COLAPIETRO F, Lleo A
    Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
    J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
    >> Share


  25. Erratum to "EASL Clinical Practice Guidelines on acute-on-chronic liver failure" [J Hepatol 79 (2023) 461-491].
    J Hepatol. 2024 May 20:S0168-8278(24)00164-8. doi: 10.1016/j.jhep.2024.
    >> Share

  26. FRANCQUE S, Krag A, Shawcross DL, Zelber-Sagi S, et al
    A Turning point in Hepatology? EASL Reflects on the First Approved Drug for MASH.
    J Hepatol. 2024 May 16:S0168-8278(24)00340-4. doi: 10.1016/j.jhep.2024.
    >> Share

  27. ZHU CX, Yan K, Chen L, Huang RR, et al
    Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma.
    J Hepatol. 2024 May 15:S0168-8278(24)00342-8. doi: 10.1016/j.jhep.2024.
    >> Share

  28. NARDELLI S, Vizzutti F, Marra F, Schepis F, et al
    Can we really advise a patient undergoing TIPS that the onset of episodic hepatic encephalopathy will not influence his/her survival?
    J Hepatol. 2024 May 9:S0168-8278(24)00339-8. doi: 10.1016/j.jhep.2024.
    >> Share

  29. ZHANG Y, Xiao F, Xie R
    Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
    J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
    >> Share

  30. YANG M, Zhang F, Liu K
    Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
    J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
    >> Share

  31. HARRISON SA, Rolph T, Knot M, Dubourg J, et al
    FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.
    J Hepatol. 2024 May 4:S0168-8278(24)00332-5. doi: 10.1016/j.jhep.2024.
    >> Share

  32. ZHU B, Guo Y, Lv S, Ling X, et al
    Hepatic phenotypes of EFL1-related Shwachman-Diamond syndrome in a biopsy-validated study.
    J Hepatol. 2024 May 3:S0168-8278(24)00328-3. doi: 10.1016/j.jhep.2024.
    >> Share

  33. FOUAD Y, Ghazinyan H, Alboraie M, Al Khatry M, et al
    Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition.
    J Hepatol. 2024;80:e194-e197.
    >> Share

  34. XIAO R, Tian Y, Zhang J, Li N, et al
    Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
    J Hepatol. 2024;80:792-804.
    >> Share

  35. CHOLANKERIL G, Kanwal F
    Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea".
    J Hepatol. 2024;80:e218-e219.
    >> Share

  36. YOUNOSSI ZM, Paik JM, Stepanova M, Ong J, et al
    Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    J Hepatol. 2024;80:694-701.
    >> Share

  37. WANG Z, Xie D, Li J, Zhai Z, et al
    Molecular force-induced liberation of transforming growth factor-beta remodels the spleen for ectopic liver regeneration.
    J Hepatol. 2024;80:753-763.
    >> Share

  38. SUN Z, Liu M, Guo J, Wang S, et al
    BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;80:e197-e199.
    >> Share

  39. XIAO MC, Jiang N, Chen LL, Liu F, et al
    TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4alpha stability.
    J Hepatol. 2024;80:778-791.
    >> Share

  40. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    >> Share

  41. XIAO H, Niu D, Zhang B
    Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
    J Hepatol. 2024;80:e207-e209.
    >> Share

  42. MA D, Li X
    Methodological challenges in studying immune-suppressive neutrophils in HCC models.
    J Hepatol. 2024;80:e215-e216.
    >> Share

  43. CIARDULLO S, Perseghin G
    Steatotic liver disease phenotypes in the United States: The impact of alcohol consumption assessment.
    J Hepatol. 2024;80:e203-e204.
    >> Share

    April 2024
  44. YANG L, Niu K, Wang J, Shen W, et al
    Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
    >> Share

  45. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
    Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
    >> Share

  46. TAN MY, Su JH
    Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
    >> Share

  47. MCGETTIGAN B, Shah V
    EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
    J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
    >> Share

  48. FU JT, Liu J, Wu WB, Chen YT, et al
    Targeting EFHD2 Inhibits Interferon-gamma Signaling and Ameliorates Non-Alcoholic Steatohepatitis.
    J Hepatol. 2024 Apr 24:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.
    >> Share

  49. CHEN K, Wang Y, Yang J, Kloting N, et al
    EMC10 modulates hepatic ER stress and steatosis in an isoform specific manner.
    J Hepatol. 2024 Apr 8:S0168-8278(24)00234-4. doi: 10.1016/j.jhep.2024.
    >> Share

  50. YIN K, Buttner M, Deligiannis IK, Strzelecki M, et al
    Polyploidisation pleiotropically buffers ageing in hepatocytes.
    J Hepatol. 2024 Apr 5:S0168-8278(24)00227-7. doi: 10.1016/j.jhep.2024.
    >> Share

  51. CHEN VL, Du X, Oliveri A, Chen Y, et al
    Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
    J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
    >> Share

  52. MOGA L, Paradis V, Bruno O, Valla D, et al
    Hepatomegaly in a patient with a history of acute myeloid leukemia.
    J Hepatol. 2024;80:e139-e142.
    >> Share

  53. TREVISANI F, Vitale A, Kudo M, Kulik L, et al
    Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal.
    J Hepatol. 2024;80:661-669.
    >> Share

  54. WANG CW, Huang PC, Dai CY, Huang JF, et al
    Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label.
    J Hepatol. 2024;80:e157-e159.
    >> Share

  55. SHIRI AM, Zhang T, Bedke T, Zazara DE, et al
    IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
    J Hepatol. 2024;80:634-644.
    >> Share

  56. SUZUKI H, Tanaka T, Yamaguchi S, Miwa K, et al
    Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD.
    J Hepatol. 2024;80:e150-e151.
    >> Share

  57. CHEN J, Zhou H, Liu K
    Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease.
    J Hepatol. 2024;80:e143-e145.
    >> Share

  58. RETAT L, Webber L, Jepsen P, Martin A, et al
    Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study.
    J Hepatol. 2024;80:543-552.
    >> Share

  59. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
    J Hepatol. 2024;80:586-595.
    >> Share

  60. YANG A, Zhu X, Zhang L, Ding Y, et al
    Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort.
    J Hepatol. 2024;80:e154-e155.
    >> Share

    March 2024
  61. HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
    Erratum to 'JAK1 promotes HDV replication and is a potential target for antiviral therapy' [J Hepatol 80 (2024) 220-231].
    J Hepatol. 2024 Mar 30:S0168-8278(24)00165-X. doi: 10.1016/j.jhep.2024.
    >> Share

  62. D'AMICO G, Perricone G
    Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
    >> Share

  63. CHAN SL, Ryoo BY, Mo F, Chan LL, et al
    Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.
    >> Share

  64. STRANDBERG R, Jepsen P, Hagstrom H
    Developing and Validating Clinical Prediction Models in Hepatology-an Overview for Clinicians.
    J Hepatol. 2024 Mar 24:S0168-8278(24)00213-7. doi: 10.1016/j.jhep.2024.
    >> Share

  65. PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
    Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
    >> Share

  66. NADIM MK, Kellum JA, Forni L, Francoz C, et al
    Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
    >> Share

  67. YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
    Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
    >> Share

  68. XU L, Zhang Y, Lin Z, Deng X, et al
    FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
    >> Share

  69. MA AT, Sole C, Juanola A, Escude L, et al
    Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
    >> Share

  70. JACHS M, Sandmann L, Hartl L, Tergast T, et al
    Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
    >> Share

  71. CHOI SH, Lee BM, Kim J, Kim DY, et al
    Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study.
    J Hepatol. 2024 Mar 9:S0168-8278(24)00154-5. doi: 10.1016/j.jhep.2024.
    >> Share

  72. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
    Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
    >> Share

  73. HAXHE S, Baldin P, Trefois P, Havelange V, et al
    Jaundice with severe leucocytosis.
    J Hepatol. 2024;80:e103-e105.
    >> Share

  74. RUSSO FP, Francque SM, Shawcross DL, Krag AA, et al
    Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations.
    J Hepatol. 2024;80:384-386.
    >> Share

  75. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    >> Share

  76. DIAZ LA, Fuentes-Lopez E, Idalsoaga F, Ayares G, et al
    Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
    J Hepatol. 2024;80:409-418.
    >> Share

  77. GE X, Desert R, Magdaleno F, Han H, et al
    Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
    J Hepatol. 2024;80:482-494.
    >> Share

  78. YOUNOSSI ZM, Alqahtani SA, Alswat K, Yilmaz Y, et al
    Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    J Hepatol. 2024;80:419-430.
    >> Share

  79. BOESCH M, Lindhorst A, Feio-Azevedo R, Brescia P, et al
    Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
    J Hepatol. 2024;80:397-408.
    >> Share

  80. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
    Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
    J Hepatol. 2024;80:467-481.
    >> Share

  81. IRUZUBIETA P, Santos-Laso A, Arias-Loste MT, Calleja JL, et al
    Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
    J Hepatol. 2024;80:e121-e123.
    >> Share

  82. LEE E, Korf H, Vidal-Puig A
    Reply to: "Liver-adipose tissue crosstalk in nonalcoholic fatty liver disease: the emerging role of remnant cholesterol": "BAT activation might improve NAFLD in patients, but this might require developing and/or maintaining functionally relevant level
    J Hepatol. 2024;80:e112-e114.
    >> Share

  83. LARRUE H, Bureau C, D'Amico G
    Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
    J Hepatol. 2024;80:e109-e110.
    >> Share

  84. LIU Y, Chen M
    Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
    J Hepatol. 2024;80:e111-e112.
    >> Share

    February 2024
  85. XIE P, Yu M, Zhang B, Yu Q, et al
    CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
    J Hepatol. 2024 Feb 23:S0168-8278(24)00129-6. doi: 10.1016/j.jhep.2024.
    >> Share

  86. BLASZKIEWICZ J, Duncan SA
    Use of stem cell-derived hepatocytes to model liver disease.
    J Hepatol. 2024 Feb 15:S0168-8278(23)05306-0. doi: 10.1016/j.jhep.2023.
    >> Share

  87. CAON E, Martins M, Hodgetts H, Blanken L, et al
    Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
    >> Share

  88. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Response to "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?".
    J Hepatol. 2024 Feb 14:S0168-8278(24)00122-3. doi: 10.1016/j.jhep.2024.
    >> Share

  89. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    >> Share

  90. YANG H, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
    J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
    >> Share

  91. ARTRU F, Reiberger T
    One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
    >> Share

  92. ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
    Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
    >> Share

  93. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    >> Share

  94. HUANG CH, Tsai MH, Lin CY
    Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
    J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
    >> Share

  95. LIU C, Guo C, Liu K
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
    >> Share

  96. T R, J B
    Endoscopic diagnosis and treatment for portal hypertension: not yet ready for clinical practice!
    J Hepatol. 2024 Feb 6:S0168-8278(24)00120-X. doi: 10.1016/j.jhep.2024.
    >> Share

  97. WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
    Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
    >> Share

  98. SILVA H, King JJ, Thorburn D, Luong TV, et al
    A rare cause of liver fibrosis in an adult patient.
    J Hepatol. 2024;80:e48-e50.
    >> Share

  99. ESLER WP, Cohen DE
    Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
    J Hepatol. 2024;80:362-377.
    >> Share

  100. ARORA U, Biswas S, Aggarwal S, Duseja A, et al
    MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
    J Hepatol. 2024;80:e89-e91.
    >> Share

  101. DI SESSA A, Guarino S, Umano GR, Miraglia Del Giudice E, et al
    MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
    J Hepatol. 2024;80:e87-e89.
    >> Share

  102. PADILLA J, Osman NM, Bissig-Choisat B, Grimm SL, et al
    Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    J Hepatol. 2024;80:282-292.
    >> Share

  103. HE L, Zheng W, Qiu K, Kong W, et al
    Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
    J Hepatol. 2024;80:e85-e87.
    >> Share

  104. KIM D, Wijarnpreecha K, Cholankeril G, Ahmed A, et al
    Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
    J Hepatol. 2024;80:e79-e81.
    >> Share

  105. JEONG S
    Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;80:e81-e82.
    >> Share

  106. CHEN L, Tao X, Zeng M, Mi Y, et al
    Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
    J Hepatol. 2024;80:e64-e66.
    >> Share

  107. SANAL MG
    Is the change from NAFLD to MASLD driven by political correctness?
    J Hepatol. 2024;80:e74-e76.
    >> Share

  108. HAGSTROM H, Vessby J, Ekstedt M, Shang Y, et al
    99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
    J Hepatol. 2024;80:e76-e77.
    >> Share

  109. PERAZZO H, Pacheco AG, Griep RH
    Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.
    J Hepatol. 2024;80:e72-e74.
    >> Share

  110. LUO N, Zhang X, Huang J, Chen H, et al
    Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
    J Hepatol. 2024;80:e70-e71.
    >> Share

  111. EL-KASSAS M, Alswat K
    Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
    J Hepatol. 2024;80:e66-e68.
    >> Share

  112. JI H, Cheng S
    Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
    J Hepatol. 2024;80:e68-e69.
    >> Share

  113. SEMMLER G, Wernly B, Datz C
    What's in a name? New nomenclature for steatotic liver disease - to be or not to be?
    J Hepatol. 2024;80:e56-e58.
    >> Share

  114. SHIPMAN KE
    Sample types and patient preparation required when adopting the new fatty liver disease nomenclature.
    J Hepatol. 2024;80:e60-e61.
    >> Share

  115. DE A, Bhagat N, Mehta M, Taneja S, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    J Hepatol. 2024;80:e61-e62.
    >> Share

  116. RATZIU V, Boursier J
    Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
    J Hepatol. 2024;80:e51-e52.
    >> Share

  117. SONG SJ, Lai JC, Wong GL, Wong VW, et al
    Can we use old NAFLD data under the new MASLD definition?
    J Hepatol. 2024;80:e54-e56.
    >> Share

  118. LI M, Xie W
    Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
    J Hepatol. 2024;80:e53-e54.
    >> Share

  119. SCHNEIDER KM, Schneider CV
    A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.
    J Hepatol. 2024;80:e58-e60.
    >> Share

  120. ZHANG Q, Wei T, Jin W, Yan L, et al
    Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    J Hepatol. 2024;80:293-308.
    >> Share

  121. LEI Z, Yu J, Wu Y, Shen J, et al
    CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
    J Hepatol. 2024;80:194-208.
    >> Share

    January 2024
  122. NING Z
    An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
    >> Share

  123. CAMPION D, Caviglia GP, Alessandria C
    Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
    J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
    >> Share

  124. NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
    Genetic cholestasis in children and adults.
    J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
    >> Share

  125. TANG R, Li Y, Chen R, Ma X, et al
    Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
    J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
    >> Share

  126. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    >> Share

  127. ESPINOZA AF, Patel RH, Patel KR, Badachhape AA, et al
    A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma.
    J Hepatol. 2024 Jan 17:S0168-8278(24)00040-0. doi: 10.1016/j.jhep.2024.
    >> Share

  128. CHAN LL, Mok K, Chan SL
    Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 17:S0168-8278(24)00044-8. doi: 10.1016/j.jhep.2024.
    >> Share

  129. OSONOI S, Takebe T
    Organoid-guided Precision Hepatology for Metabolic Liver Disease.
    J Hepatol. 2024 Jan 16:S0168-8278(24)00038-2. doi: 10.1016/j.jhep.2024.
    >> Share

  130. NAKANO M, Kawaguchi M, Kawaguchi T
    Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
    J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
    >> Share

  131. JACHS M, Hartl L, Simbrunner B, Semmler G, et al
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
    >> Share

  132. SONG Q, Zhang X, Yu J
    Reply to "Stop Using the Misidentified Cell Line - LO2 as a Human Hepatocyte".
    J Hepatol. 2024 Jan 4:S0168-8278(24)00006-0. doi: 10.1016/j.jhep.2023.
    >> Share

  133. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    >> Share

  134. SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
    Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05355-2. doi: 10.1016/j.jhep.2023.
    >> Share

  135. TERGAST TL, Maasoumy B
    The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
    >> Share

  136. ZHENG C, Wang L, Zou T, Lian S, et al
    Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
    >> Share

  137. SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
    SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2024;80:10-19.
    >> Share

  138. BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
    Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
    J Hepatol. 2024;80:73-81.
    >> Share

  139. THOMAIDES-BREARS H, Banerjee R, Banerjee A
    Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank".
    J Hepatol. 2024;80:e24-e25.
    >> Share

  140. KAFFE E, Tisi A, Magkrioti C, Aidinis V, et al
    Bioactive signalling lipids as drivers of chronic liver diseases.
    J Hepatol. 2024;80:140-154.
    >> Share

  141. XIANG X, Wei Y, Zhao K
    Reassessing the causal relationship between liver diseases and cardiovascular outcomes.
    J Hepatol. 2024;80:e20-e22.
    >> Share

  142. DIAZ-FONTENLA F, Caballero-Marcos A, Peligros I, Vicario Moreno JL, et al
    Unusual early post-transplant hepatic dysfunction.
    J Hepatol. 2024;80:e11-e13.
    >> Share

    December 2023
  143. ZHANG F, Zhang M, Wang L, Zhuge Y, et al
    Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05368-0. doi: 10.1016/j.jhep.2023.
    >> Share

  144. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    >> Share

  145. TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
    A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
    >> Share

  146. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    >> Share

  147. LEHRICH BM, Zhang J, Monga SP, Dhanasekaran R, et al
    Battle of the Biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
    J Hepatol. 2023 Dec 15:S0168-8278(23)05307-2. doi: 10.1016/j.jhep.2023.
    >> Share

  148. VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
    Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
    J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
    >> Share

  149. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
    >> Share

  150. RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
    NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
    J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
    >> Share

  151. FAN W, Cao D, Yang B, Wang J, et al
    Hepatic prohibitin 1 and methionine adenosyltransferase alpha1 defend against primary and secondary liver cancer metastasis.
    J Hepatol. 2023 Dec 2:S0168-8278(23)05298-4. doi: 10.1016/j.jhep.2023.
    >> Share

  152. ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
    A rare cause of painful hepatomegaly.
    J Hepatol. 2023;79:e228-e230.
    >> Share


  153. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement.
    J Hepatol. 2023;79:1347-1348.
    >> Share

  154. HUTCHISON AL, Tavaglione F, Romeo S, Charlton M, et al
    Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
    J Hepatol. 2023;79:1524-1541.
    >> Share

  155. MOHR I, Poujois A, Ala A, Weiss KH, et al
    Reply to: "Early neurological worsening in Wilson disease: The need for an evidence-based definition".
    J Hepatol. 2023;79:e243.
    >> Share

  156. MENG Y, Ye F, Nie P, Zhao Q, et al
    Immunosuppressive CD10(+)ALPL(+) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.
    J Hepatol. 2023;79:1435-1449.
    >> Share

  157. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
    J Hepatol. 2023;79:e233-e234.
    >> Share

  158. SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
    Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    J Hepatol. 2023;79:1366-1373.
    >> Share

  159. NEWSOME PN, Ambery P
    Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
    J Hepatol. 2023;79:1557-1565.
    >> Share

  160. LITWIN T, Czlonkowska A, Smolinski L
    Early neurological worsening in Wilson disease: The need for an evidence-based definition.
    J Hepatol. 2023;79:e241-e242.
    >> Share

  161. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
    A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    J Hepatol. 2023;79:1542-1556.
    >> Share

  162. LONG L, Zhou X
    Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
    J Hepatol. 2023;79:e232-e233.
    >> Share

    November 2023
  163. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    >> Share

  164. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
    ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
    J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
    >> Share

  165. BERASAIN C
    When you eat and when you sleep matters: circadian dysfunction revealed as a direct hepatic carcinogen in a humanized mouse model.
    J Hepatol. 2023 Nov 17:S0168-8278(23)05277-7. doi: 10.1016/j.jhep.2023.
    >> Share

  166. CELSA C, Cabibbo G, Am Fulgenzi C, Scheiner B, et al
    Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    J Hepatol. 2023 Nov 14:S0168-8278(23)05272-8. doi: 10.1016/j.jhep.2023.
    >> Share

  167. SHAO T, Chen YL
    Stop using the misidentified cell line - LO2 as a human hepatocyte.
    J Hepatol. 2023 Nov 9:S0168-8278(23)05268-6. doi: 10.1016/j.jhep.2023.
    >> Share

  168. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    >> Share

  169. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
    >> Share

  170. TELLEZ L, Payance A, Tjwa E, Del Cerro MJ, et al
    EASL-ERN position paper on liver involvement in patients with Fontan-type circulation.
    J Hepatol. 2023;79:1270-1301.
    >> Share

  171. ROCA-FERNANDEZ A, Banerjee R, Thomaides-Brears H, Telford A, et al
    Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
    J Hepatol. 2023;79:1085-1095.
    >> Share

    October 2023
  172. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
    J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
    >> Share

  173. BIBO W, Hao S, Yating W, Fucheng L, et al
    Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
    J Hepatol. 2023 Oct 31:S0168-8278(23)05183-8. doi: 10.1016/j.jhep.2023.
    >> Share

  174. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
    Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
    J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
    >> Share

  175. FERNANDEZ-GARZA LE
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
    J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
    >> Share

  176. MUCKE MM, Fong S, Foster GR, Lillicrap D, et al
    Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists.
    J Hepatol. 2023 Oct 25:S0168-8278(23)05229-7. doi: 10.1016/j.jhep.2023.
    >> Share

  177. RATZIU V, Hompesch M, Petitjean M, Serdjebi C, et al
    Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.
    J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.
    >> Share

  178. CAMPION D, Ponzo P, Risso A, Caropreso P, et al
    A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
    J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
    >> Share

  179. MAIWALL R, Rao Pasupuleti SS, Sarin SK
    AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
    J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
    >> Share

  180. ZHANG L, Xu J, Zhou S, Yao F, et al
    Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05170-X. doi: 10.1016/j.jhep.2023.
    >> Share

  181. CHEN X, Pan J, Zhu Y
    Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
    J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
    >> Share

  182. KANG MG, Lee CH, Shen C, Kim JS, et al
    Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea.
    J Hepatol. 2023 Oct 10:S0168-8278(23)05166-8. doi: 10.1016/j.jhep.2023.
    >> Share

  183. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    >> Share

  184. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
    Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
    >> Share

  185. GRONBAEK L, Gronbaek H
    Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
    >> Share

  186. TRUSSONI CE, LaRusso NF
    Macrophages make a difference in cholestatic liver diseases - but how?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
    >> Share

  187. ABERG F, Savikko J, Eerola V, Nordin A, et al
    High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
    >> Share

  188. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    >> Share

  189. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    >> Share

  190. GROBA SR, Soehnlein O
    DRANquilizing neutrophil function in chronic liver disease.
    J Hepatol. 2023;79:885-887.
    >> Share

  191. ROMERO-GOMEZ M, Lawitz E, Shankar RR, Chaudhri E, et al
    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2023;79:888-897.
    >> Share

  192. LI L, Wang Z, Jiang Y
    Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.
    J Hepatol. 2023;79:e164-e165.
    >> Share

  193. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Retraction notice to "Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy" [J Hepatol 62 (3) (2015) 647-656].
    J Hepatol. 2023;79:1072.
    >> Share

    September 2023

  194. Corrigendum to "EASL Clinical Practice Guidelines on haemochromatosis" [J Hepatol 2022 (77) 479-502].
    J Hepatol. 2023 Sep 26:S0168-8278(23)05088-2. doi: 10.1016/j.jhep.2023.
    >> Share


  195. Corrigendum to "EASL clinical practice guidelines on the management of hepatic encephalopathy" [J Hepatol 2022 (77) 807-824].
    J Hepatol. 2023 Sep 26:S0168-8278(23)05090-0. doi: 10.1016/j.jhep.2023.
    >> Share


  196. Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
    J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
    >> Share


  197. Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
    J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
    >> Share

  198. LALEMAN W, Vanderschueren E, Mehdi ZS, Wiest R, et al
    Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments.
    J Hepatol. 2023 Sep 18:S0168-8278(23)05101-2. doi: 10.1016/j.jhep.2023.
    >> Share


  199. Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].
    J Hepatol. 2023 Sep 17:S0168-8278(23)05089-4. doi: 10.1016/j.jhep.2023.
    >> Share

  200. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    >> Share

  201. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    >> Share

  202. CHEN X, Chen S, Pang J, Huang R, et al
    Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
    J Hepatol. 2023 Sep 5:S0168-8278(23)05077-8. doi: 10.1016/j.jhep.2023.
    >> Share

  203. WANG Q, Bu Q, Zhou H, Lu L, et al
    Reply to?"Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis".
    J Hepatol. 2023 Sep 4:S0168-8278(23)05076-6. doi: 10.1016/j.jhep.2023.
    >> Share


  204. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy.
    J Hepatol. 2023;79:768-828.
    >> Share

  205. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
    A global research priority agenda to advance public health responses to fatty liver disease.
    J Hepatol. 2023;79:618-634.
    >> Share

  206. FUNDORA Y, Hessheimer AJ, Fondevila C
    Reply to: "Reconstruction for complex portal vein thrombosis - Anatomical if possible".
    J Hepatol. 2023;79:e131-e133.
    >> Share

  207. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    >> Share

  208. BOURSIER J, Roux M, Sanyal AJ
    Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
    J Hepatol. 2023;79:e128-e129.
    >> Share

  209. HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
    NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
    J Hepatol. 2023;79:758-767.
    >> Share

  210. WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
    Changing epidemiology, global trends and implications for outcomes of NAFLD.
    J Hepatol. 2023;79:842-852.
    >> Share

  211. LIANG JX, Ampuero J, Niu H, Imajo K, et al
    An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
    J Hepatol. 2023;79:592-604.
    >> Share

  212. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    >> Share

  213. DURAN M, Alfarah J, Hann A, Perera MTPR, et al
    Reconstruction for complex portal vein thrombosis - Anatomical if possible.
    J Hepatol. 2023;79:e129-e131.
    >> Share

  214. NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
    Agile scores are a good predictor of liver-related events in patients with NAFLD.
    J Hepatol. 2023;79:e126-e127.
    >> Share

    August 2023
  215. CHEN R, Huang B, Lian M, Wei Y, et al
    A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
    >> Share

  216. EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
    Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
    >> Share

  217. LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
    Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
    >> Share

  218. BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
    Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
    >> Share

  219. CAI J, Wang J, Jiang C, Ye L, et al
    Combined inhibition of surface CD51 and gamma-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.
    J Hepatol. 2023 Aug 19:S0168-8278(23)05062-6. doi: 10.1016/j.jhep.2023.
    >> Share

  220. WAN YM, Wu HM, Huang SQ, Li HY, et al
    A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B." (J Hepatol. 2023 May;78(5):926-936.).
    J Hepatol. 2023 Aug 11:S0168-8278(23)05051-1. doi: 10.1016/j.jhep.2023.
    >> Share

  221. UPADHYAY KK, Du X, Chen Y, Buscher B, et al
    A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohorts.
    J Hepatol. 2023 Aug 9:S0168-8278(23)05049-3. doi: 10.1016/j.jhep.2023.
    >> Share

  222. ZANETTO A, Pelizzaro F, Bellan E, Sbaraglia M, et al
    Multiple hepatic cysts in an adult male.
    J Hepatol. 2023;79:e64-e66.
    >> Share

  223. RATZIU V, Tacke F
    At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH.
    J Hepatol. 2023;79:261-262.
    >> Share

  224. TSOCHATZIS EA
    Screening for liver fibrosis - sequential non-invasive testing works best.
    J Hepatol. 2023;79:263-265.
    >> Share

  225. KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
    Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    J Hepatol. 2023;79:296-313.
    >> Share

  226. FERNANDEZ-CHECA JC, Torres S, Garcia-Ruiz C
    HILPDA, a new player in NASH-driven HCC, links hypoxia signaling with ceramide synthesis.
    J Hepatol. 2023;79:269-272.
    >> Share

  227. SINGAL AG, Marrero J, Parikh ND
    Reply to: "Correction for length bias reduces the mortality benefit from hepatocellular carcinoma surveillance".
    J Hepatol. 2023;79:e90-e92.
    >> Share

  228. ROMA K, Mohammed S, Sieck B, Naik K, et al
    Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
    J Hepatol. 2023;79:581-584.
    >> Share

  229. MOHR I, Pfeiffenberger J, Eker E, Merle U, et al
    Neurological worsening in Wilson disease - clinical classification and outcome.
    J Hepatol. 2023;79:321-328.
    >> Share

  230. KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
    Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    J Hepatol. 2023;79:277-286.
    >> Share

  231. MEYER T, Galani S, Lopes A, Vogel A, et al
    Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease.
    J Hepatol. 2023;79:e73-e76.
    >> Share

  232. POVERO D, Chen Y, Johnson SM, McMahon CE, et al
    HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
    J Hepatol. 2023;79:378-393.
    >> Share

  233. TACKE F, Puengel T, Loomba R, Friedman SL, et al
    An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    J Hepatol. 2023;79:552-566.
    >> Share

  234. LE MH, Le DM, Baez TC, Wu Y, et al
    Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
    J Hepatol. 2023;79:287-295.
    >> Share

  235. AYYALA-SOMAYAJULA D, Dodge JL, Farias A, Terrault N, et al
    Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States.
    J Hepatol. 2023;79:329-339.
    >> Share

  236. YAHOO N, Dudek M, Knolle P, Heikenwalder M, et al
    Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    J Hepatol. 2023;79:538-551.
    >> Share

  237. BAROUKI R, Samson M, Blanc EB, Colombo M, et al
    The exposome and liver disease - how environmental factors affect liver health.
    J Hepatol. 2023;79:492-505.
    >> Share

  238. PENG J, Lu M, Peng Y, Tang X, et al
    Global incidence of primary liver cancer by etiology among children, adolescents, and young adults.
    J Hepatol. 2023;79:e92-e94.
    >> Share

    July 2023
  239. PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
    Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
    >> Share

  240. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
    Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
    >> Share

  241. TAPPER EB, Bajaj JS
    Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
    >> Share

  242. VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
    >> Share

  243. KUTER DJ, Bonkovsky HL, Monroy S, Ross G, et al
    Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    J Hepatol. 2023 Jul 19:S0168-8278(23)04933-4. doi: 10.1016/j.jhep.2023.
    >> Share

  244. LU Y, Sun Q, Guan Q, Zhang Z, et al
    The XOR-IDH3alpha axis controls macrophage polarization in hepatocellular carcinoma.
    J Hepatol. 2023 Jul 18:S0168-8278(23)04984-X. doi: 10.1016/j.jhep.2023.
    >> Share

  245. SONG Q, Zhang X, Liu W, Wei H, et al
    Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    J Hepatol. 2023 Jul 15:S0168-8278(23)04981-4. doi: 10.1016/j.jhep.2023.
    >> Share

  246. GUAN MC, Ding Q, Zhu H
    Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over one year ?
    J Hepatol. 2023 Jul 4:S0168-8278(23)04937-1. doi: 10.1016/j.jhep.2023.
    >> Share

  247. AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
    Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
    J Hepatol. 2023;79:79-92.
    >> Share


  248. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
    J Hepatol. 2023;79:4-5.
    >> Share

  249. CRAIG AJ, Silveira MAD
    The role of ETV4 in HCC: How transcription factors can inform immunotherapy combination treatments.
    J Hepatol. 2023;79:19-21.
    >> Share

  250. ROWE IA
    Understanding the risks and benefits of policy action in NAFLD.
    J Hepatol. 2023;79:22-24.
    >> Share

  251. BERAZA N
    Ketohexokinase-C: The mechanistic link between dietary sugars and protein acetylation during liver steatosis.
    J Hepatol. 2023;79:16-18.
    >> Share

  252. D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
    MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    J Hepatol. 2023;79:141-149.
    >> Share

  253. HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
    Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
    J Hepatol. 2023;79:150-166.
    >> Share

  254. VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
    Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
    J Hepatol. 2023;79:e23-e24.
    >> Share

  255. NAHON P, Trepo E
    Reply to: "Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses".
    J Hepatol. 2023;79:e35-e37.
    >> Share

  256. SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
    Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
    J Hepatol. 2023;79:e27-e28.
    >> Share

  257. ALLEN AM, Lazarus JV, Younossi ZM
    Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
    J Hepatol. 2023;79:209-217.
    >> Share

  258. PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
    From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
    J Hepatol. 2023;79:e25-e27.
    >> Share

  259. RIDOLA L, Riggio O
    Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
    J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
    >> Share

  260. LI Z, Hu Y, Zou B
    The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
    J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  261. AGRAWAL D, Ariga KK
    Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
    J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
    >> Share

  262. YANG H, Kim JH, Han JW, Lee SK, et al
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?'.
    J Hepatol. 2023 Jun 27:S0168-8278(23)00425-7. doi: 10.1016/j.jhep.2023.
    >> Share

  263. CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
    Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
    J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
    >> Share

  264. NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
    Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
    J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
    >> Share

  265. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  266. ZHANG X, Sharma P, Maschmeyer P, Hu Y, et al
    GARP on hepatic stellate cells is essential for the development of liver fibrosis.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00422-1. doi: 10.1016/j.jhep.2023.
    >> Share

  267. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
    Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
    >> Share

  268. TAVABIE O
    Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
    J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
    >> Share

  269. BERTOLETTI A, Le Bert N, Tan AT, Boni C, et al
    End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB, by Huang et al. J Hepatology 77, 42-54 (2022).
    J Hepatol. 2023 Jun 10:S0168-8278(23)00408-7. doi: 10.1016/j.jhep.2023.
    >> Share

  270. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    >> Share

  271. CLAVERIA-CABELLO A, Herranz JM, Latasa MU, Arechederra M, et al
    Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00405-1. doi: 10.1016/j.jhep.2023.
    >> Share

  272. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    >> Share

  273. ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
    Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
    >> Share

  274. LIU X, Wen X, Lu F
    Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
    J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
    >> Share

  275. SENZOLO M, Garcia-Pagan JC
    A major research gap: the use of anticoagulants in cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
    >> Share

  276. FU W, Liu C, Li J
    Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jun 8:S0168-8278(23)00411-7. doi: 10.1016/j.jhep.2023.
    >> Share

  277. ALBILLOS A, Guerrero A, Tellez L
    Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
    J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
    >> Share

  278. RAEVENS S, Fallon MB
    Fingolimod as a sphingolipid modulator in hepatopulmonary syndrome: a critical review.
    J Hepatol. 2023 Jun 8:S0168-8278(23)00406-3. doi: 10.1016/j.jhep.2023.
    >> Share

  279. FONDEVILA MF, Schnabl B
    Intestinal clock modulates rhythmic hepatic metabolism.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00350-1. doi: 10.1016/j.jhep.2023.
    >> Share

  280. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
    J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
    >> Share

  281. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    >> Share

  282. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    >> Share

  283. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    >> Share

  284. CLIFT AK, Hagness M, Lehmann K, Rosen CB, et al
    Transplantation for metastatic liver disease.
    J Hepatol. 2023;78:1137-1146.
    >> Share

  285. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    >> Share

  286. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    >> Share

  287. TSOCHATZIS EA, Watt KD, VanWagner LB, Verna EC, et al
    Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease.
    J Hepatol. 2023;78:1089-1104.
    >> Share

  288. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    >> Share

    May 2023
  289. LALLOYER F, Mogilenko DA, Verrijken A, Haas JT, et al
    Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis.
    J Hepatol. 2023 May 23:S0168-8278(23)00341-0. doi: 10.1016/j.jhep.2023.
    >> Share

  290. HE F, Jiang H, Peng C, Wang T, et al
    Hepatic glucuronyl C5-epimerase combats obesity by stabilizing GDF15.
    J Hepatol. 2023 May 20:S0168-8278(23)00340-9. doi: 10.1016/j.jhep.2023.
    >> Share

  291. INNES H, Nahon P
    Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
    J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
    >> Share

  292. LINDEN D, Romeo S
    Mini-Review for Journal of HepatologyTherapeutic opportunities for the treatment of NASH with genetically validated targets.
    J Hepatol. 2023 May 17:S0168-8278(23)00335-5. doi: 10.1016/j.jhep.2023.
    >> Share

  293. SCHAEFFER S, Gupta B, Calatayud AL, Calderaro J, et al
    RSK2 inactivation cooperates with AXIN1 inactivation or ss-catenin activation to promote hepatocarcinogenesis.
    J Hepatol. 2023 May 16:S0168-8278(23)00333-1. doi: 10.1016/j.jhep.2023.
    >> Share

  294. SHAWCROSS DL, Thabut D, Amodio P
    Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
    >> Share

  295. ZHANG C, Ding WX
    Caveats to link in vitro mechanistic mitophagy studies to the pathogenesis of non-alcoholic steatohepatitis.
    J Hepatol. 2023 May 6:S0168-8278(23)00319-7. doi: 10.1016/j.jhep.2023.
    >> Share

  296. ASHRAF MU, De A, Rose S
    Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns.
    J Hepatol. 2023 May 3:S0168-8278(23)00315-X. doi: 10.1016/j.jhep.2023.
    >> Share

  297. LARRUE H, D'Amico G, Olivas P, Lv Y, et al
    TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
    J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
    >> Share

  298. YIN JL, Ala A, Miquel R
    Histology - further raising the diagnostic bar in chronic liver disease.
    J Hepatol. 2023;78:e162-e164.
    >> Share

  299. FUNDORA Y, Fuster-Anglada C, Bassaganyas C, Toapanta D, et al
    An infrequent cause of spontaneous liver rupture.
    J Hepatol. 2023;78:e160-e161.
    >> Share

  300. DI MARTINO V
    Methotrexate-induced liver fibrosis: The end of a long-held belief.
    J Hepatol. 2023;78:896-897.
    >> Share

  301. HARRISON SA, Thang C, Bolze S, Dewitt S, et al
    Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    J Hepatol. 2023;78:914-925.
    >> Share

  302. LEE E, Korf H, Vidal-Puig A
    An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.
    J Hepatol. 2023;78:1048-1062.
    >> Share

  303. ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
    A human liver organoid screening platform for DILI risk prediction.
    J Hepatol. 2023;78:998-1006.
    >> Share

  304. AJMERA V, Loomba R
    Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues".
    J Hepatol. 2023;78:e168-e169.
    >> Share

  305. FALKEVALL A, Mehlem A, Folestad E, Ning FC, et al
    Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    J Hepatol. 2023;78:901-913.
    >> Share

  306. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
    Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
    J Hepatol. 2023;78:989-997.
    >> Share

  307. SURIAL B, Ramirez Mena A, Roumet M, Limacher A, et al
    External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
    J Hepatol. 2023;78:947-957.
    >> Share

  308. RATZIU V, Charlton M
    Rational combination therapy for NASH: Insights from clinical trials and error.
    J Hepatol. 2023;78:1073-1079.
    >> Share

  309. BINET Q, Hermans MP, Lanthier N
    Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues.
    J Hepatol. 2023;78:e166-e167.
    >> Share

  310. ZHANG H, Peng Y, Tang X
    Comment on: Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
    J Hepatol. 2023;78:e177-e178.
    >> Share

  311. DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
    Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
    J Hepatol. 2023;78:e165-e166.
    >> Share

    April 2023
  312. BERG T, Krag A
    The future of hepatology - "The best way to predict your future is to create it".
    J Hepatol. 2023 Apr 28:S0168-8278(23)00308-2. doi: 10.1016/j.jhep.2023.
    >> Share

  313. MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
    A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
    >> Share

  314. PASSMAN AM, Haughey MJ, Carlotti E, Williams MJ, et al
    Hepatocytes undergo punctuated expansion dynamics from a periportal stem cell niche in normal human liver.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00223-4. doi: 10.1016/j.jhep.2023.
    >> Share

  315. AGUILAR-BRAVO B, Arino S, Blaya D, Pose E, et al
    Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00236-2. doi: 10.1016/j.jhep.2023.
    >> Share

  316. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    >> Share

  317. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
    The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
    J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
    >> Share

  318. YI H, Leng Q, Zhou J, Peng S, et al
    Do open access articles have a citation advantage in Journal of Hepatology?
    J Hepatol. 2023 Apr 19:S0168-8278(23)00238-6. doi: 10.1016/j.jhep.2023.
    >> Share

  319. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
    Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
    J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
    >> Share

  320. JIN K, Shi Y, Zhang H, Zhangyuan G, et al
    A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
    J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
    >> Share

  321. VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
    Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
    J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
    >> Share

  322. YEOH BS, Vijay-Kumar M
    Gut microbiota lends a helping hand to nurse liver regeneration.
    J Hepatol. 2023;78:681-683.
    >> Share

  323. LIU Y, Xun Z, Ma K, Liang S, et al
    Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    J Hepatol. 2023;78:770-782.
    >> Share

  324. HADJIHAMBI A, Pellerin L
    Reply to: "Is NAFLD a key driver of brain dysfunction?".
    J Hepatol. 2023;78:e130-e131.
    >> Share

  325. RASMUSSEN DGK, Anstee QM, Torstenson R, Golding B, et al
    NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
    J Hepatol. 2023;78:852-865.
    >> Share

  326. LI C, He WQ
    Global prediction of primary liver cancer incidences and mortality in 2040.
    J Hepatol. 2023;78:e144-e146.
    >> Share

  327. WANG Y, Wang Y, Duan G, Yang H, et al
    NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis.
    J Hepatol. 2023;78:e136-e139.
    >> Share

  328. SANDFORTH L, El-Agroudy NN, Birkenfeld AL
    Is NAFLD a key driver of brain dysfunction?
    J Hepatol. 2023;78:e129-e130.
    >> Share

  329. CHUNG DH, Zheng M, Bale AE, Vilarinho S, et al
    Hepatology Genome Rounds: An interdisciplinary approach to integrate genomic data in clinical practice.
    J Hepatol. 2023 Apr 1:S0168-8278(23)00208-8. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  330. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  331. PAIS R, Cariou B, Noureddin M, Francque S, et al
    A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials.
    J Hepatol. 2023 Mar 29:S0168-8278(23)00189-7. doi: 10.1016/j.jhep.2023.
    >> Share

  332. BAWEJA S, Kumari A, Negi P, Tomar A, et al
    Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
    >> Share

  333. HE F, Zhang P, Liu J, Wang R, et al
    ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00193-9. doi: 10.1016/j.jhep.2023.
    >> Share

  334. LISMAN T, Bernal W, Luyendyk JP
    Anticoagulation to prevent disease progression in patients with cirrhosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
    >> Share

  335. JAGADISAN B, Dhawan A
    Multidisciplinary approach and reactive immunosuppression for gene therapy related hepatotoxicity.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00197-6. doi: 10.1016/j.jhep.2023.
    >> Share


  336. EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
    >> Share

  337. MANGINI C, Gagliardi R, Causin F, Angeli P, et al
    Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
    J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
    >> Share

  338. RIMASSA L, Finn RS, Sangro B
    Combination immunotherapy for hepatocellular carcinoma.
    J Hepatol. 2023 Mar 16:S0168-8278(23)00178-2. doi: 10.1016/j.jhep.2023.
    >> Share

  339. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆)" [J Hepatol (2020) 505-515].
    J Hepatol. 2023 Mar 13:S0168-8278(23)00160-5. doi: 10.1016/j.jhep.2023.
    >> Share

  340. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Corrigendum to "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease" [J Hepatol 77 (2022) 918-930].
    J Hepatol. 2023 Mar 13:S0168-8278(23)00030-2. doi: 10.1016/j.jhep.2023.
    >> Share

  341. XIE M, Lin Z, Ji X, Luo X, et al
    FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    J Hepatol. 2023 Mar 10:S0168-8278(23)00172-1. doi: 10.1016/j.jhep.2023.
    >> Share

  342. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    >> Share

  343. VIOLI F, Pignatelli P, Cammisotto V
    Platelet defetcts in cirrhosis: fact or fiction?
    J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
    >> Share

  344. TAN J, Fan W, Liu T, Zhu B, et al
    TREM2(+) macrophages suppress CD8(+) T cell infiltration after transarterial chemoembolization in hepatocellular carcinoma.
    J Hepatol. 2023 Mar 6:S0168-8278(23)00164-2. doi: 10.1016/j.jhep.2023.
    >> Share

  345. NOGUEIRAS R, Aspichueta P
    Expanding the roles of the renin-angiotensin system: Drug-induced liver injury.
    J Hepatol. 2023;78:457-459.
    >> Share

  346. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    >> Share

  347. TROVATO FM, Zia R, Artru F, Mujib S, et al
    Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure.
    J Hepatol. 2023;78:558-573.
    >> Share

  348. BANTEL H, Schulze-Osthoff K
    Non-invasive tests for evaluating treatment response in NAFLD.
    J Hepatol. 2023;78:e101-e102.
    >> Share

  349. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    >> Share

  350. DURAND F, Kellum JA, Nadim MK
    Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
    >> Share

  351. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
    Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
    >> Share

    February 2023
  352. GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
    Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
    J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
    >> Share

  353. SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
    International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
    J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
    >> Share

  354. ZENG L, Li X, Peng Z
    Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
    J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
    >> Share

  355. ROBINS CJG, Buchanan RM
    Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance.
    J Hepatol. 2023 Feb 21:S0168-8278(23)00104-6. doi: 10.1016/j.jhep.2023.
    >> Share

  356. HOARE M
    Mouse models of hepatocyte biology - known unknowns.
    J Hepatol. 2023 Feb 11:S0168-8278(23)00088-0. doi: 10.1016/j.jhep.2023.
    >> Share

  357. EBADI M, Burra P, Zanetto A, Montano-Loza AJ, et al
    Current Treatment Strategies and Future Possibilities for Sarcopenia in Cirrhosis.
    J Hepatol. 2023 Feb 10:S0168-8278(23)00090-9. doi: 10.1016/j.jhep.2023.
    >> Share

  358. FABRELLAS N, Kunzler-Heule P, Olofson A, Jack K, et al
    Nursing Care For Patients With Cirrhosis.
    J Hepatol. 2023 Feb 6:S0168-8278(23)00082-X. doi: 10.1016/j.jhep.2023.
    >> Share

  359. YUEN VW, Chiu DK, Law CT, Cheu JW, et al
    Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    J Hepatol. 2023;78:376-389.
    >> Share

  360. KISHORE SB, Lewindon P, Noble C, Balouch F, et al
    Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.
    J Hepatol. 2023;78:e57-e59.
    >> Share

  361. LI Z, Zhang B, Li J, Tao Z, et al
    Assessing causal relationship between non-alcoholic fatty liver disease and risk of atrial fibrillation.
    J Hepatol. 2023;78:e63-e65.
    >> Share

  362. STAUFER K, Mangal B, Trauner M
    Detection of unreported alcohol consumption in fatty liver disease.
    J Hepatol. 2023;78:e67-e69.
    >> Share

  363. ROEHLEN N, Muller M, Nehme Z, Crouchet E, et al
    Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
    J Hepatol. 2023;78:343-355.
    >> Share

  364. FROMENTY B, Roden M
    Mitochondrial alterations in fatty liver diseases.
    J Hepatol. 2023;78:415-429.
    >> Share

  365. BERASAIN C, Arechederra M, Argemi J, Fernandez-Barrena MG, et al
    Loss of liver function in chronic liver disease: An identity crisis.
    J Hepatol. 2023;78:401-414.
    >> Share

  366. PARADIS V, Zucman-Rossi J
    Pathogenesis of primary liver carcinomas.
    J Hepatol. 2023;78:448-449.
    >> Share

  367. HAGSTROM H, Ekstedt M
    Considerations in the search for under-reported alcohol consumption in NAFLD.
    J Hepatol. 2023;78:e66-e67.
    >> Share

  368. CARLSON S, Vaz K, Peterson A
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
    J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
    >> Share

    January 2023
  369. SPOSITO C, Cucchetti A, Mazzaferro V
    Survival Benefit Of Lymphadenectomy For Intrahepatic Cholangiocarcinoma: It Might Be Gold Even If It Does Not Glitter.
    J Hepatol. 2023 Jan 31:S0168-8278(23)00073-9. doi: 10.1016/j.jhep.2023.
    >> Share

  370. ZANETTO A, Northup P, Roberts L, Senzolo M, et al
    Hemostasis in cirrhosis: understanding destabilising factors during acute decompensation.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00022-3. doi: 10.1016/j.jhep.2023.
    >> Share

  371. MAY S, Muller M, Livingstone CR, Skalka GL, et al
    Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration.
    J Hepatol. 2023 Jan 23:S0168-8278(23)00021-1. doi: 10.1016/j.jhep.2023.
    >> Share

  372. FUNDORA Y, Hessheimer AJ, Del Prete L, Maroni L, et al
    Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
    J Hepatol. 2023 Jan 20:S0168-8278(23)00018-1. doi: 10.1016/j.jhep.2023.
    >> Share

  373. YIN Y, Sichler A, Ecker J, Laschinger M, et al
    Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00009-0. doi: 10.1016/j.jhep.2022.
    >> Share

  374. JI R, Chen J, Xie Y, Dou X, et al
    Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00015-6. doi: 10.1016/j.jhep.2022.
    >> Share

  375. TAO L, Yang G, Sun T, Tao J, et al
    Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
    >> Share

  376. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
    3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
    >> Share

  377. JI D, Tan L, Yang Y
    Reply to "Biejia-Ruangan compound and incidence of hepatocellular carcinoma".
    J Hepatol. 2023 Jan 13:S0168-8278(23)00008-9. doi: 10.1016/j.jhep.2023.
    >> Share

  378. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581].
    J Hepatol. 2023 Jan 11:S0168-8278(22)03321-9. doi: 10.1016/j.jhep.2022.
    >> Share

  379. POVERO D
    Novel oncometabolites and metabolic checkpoints involved in hepatocellular carcinoma development.
    J Hepatol. 2023 Jan 11:S0168-8278(23)00001-6. doi: 10.1016/j.jhep.2023.
    >> Share

  380. MAGYAR CTJ, Beldi G, Banz V
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma - Letter to the editor.
    J Hepatol. 2023 Jan 5:S0168-8278(22)03474-2. doi: 10.1016/j.jhep.2022.
    >> Share

  381. CHEN L, Fan Z, Zhao Y, Yang H, et al
    Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03476-6. doi: 10.1016/j.jhep.2022.
    >> Share

  382. ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
    A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
    >> Share

  383. MOULTON CD, Staite E, Winkley K, Heneghan MA, et al
    The association between liver fibrosis and cognitive impairment in type 2 diabetes.
    J Hepatol. 2023;78:e18-e20.
    >> Share

  384. SHEN Y, Chen H, Wu SD, Jiang W, et al
    Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.
    J Hepatol. 2023;78:e33-e34.
    >> Share

  385. BOETTLER T, Krag A, Berg T
    Reply to: "Depiction of alcohol-related liver disease in the EASL International Liver Congress".
    J Hepatol. 2023;78:e38-e39.
    >> Share

  386. TRIPATHI M, Kumar Singh B, Yen PM
    Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin".
    J Hepatol. 2023;78:e35-e36.
    >> Share

  387. CARDINALE V, Carpino G, Overi D, Safarikia S, et al
    Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential.
    J Hepatol. 2023;78:165-179.
    >> Share

  388. ABERG F, Byrne CD, Pirola CJ, Mannisto V, et al
    Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease.
    J Hepatol. 2023;78:191-206.
    >> Share

  389. PARK J, Zhao Y, Zhang F, Zhang S, et al
    IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    J Hepatol. 2023;78:45-56.
    >> Share

  390. SPENCE JD
    B vitamins for NASH: Use methylcobalamin, not cyanocobalamin.
    J Hepatol. 2023;78:e34-e35.
    >> Share

  391. MA T, Yu X, Sun M
    Relationship between non-alcoholic fatty liver disease and atrial fibrillation: Assessment of latest evidence.
    J Hepatol. 2023;78:e31-e33.
    >> Share

  392. HADJIHAMBI A, Konstantinou C, Klohs J, Monsorno K, et al
    Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
    J Hepatol. 2023;78:180-190.
    >> Share

  393. GAO X, Lv F, He X, Zhao Y, et al
    Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
    J Hepatol. 2023;78:16-27.
    >> Share

  394. GOODHEART RH, Ayonrinde OT
    Depiction of alcohol-related liver disease in the EASL International Liver Congress.
    J Hepatol. 2023;78:e36-e38.
    >> Share

    December 2022
  395. MCPHAIL MJ, Patel VC, Carter B
    Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
    J Hepatol. 2022 Dec 31:S0168-8278(22)03471-7. doi: 10.1016/j.jhep.2022.
    >> Share

  396. INNES H
    Genetic data not yet a "game-changer" for predicting individualised hepatocellular carcinoma risk.
    J Hepatol. 2022 Dec 30:S0168-8278(22)03467-5. doi: 10.1016/j.jhep.2022.
    >> Share

  397. LIN H, Cheuk-Yan Yiu D, Chin S, Liu K, et al
    Metformin in patients with hepatocellular carcinoma receiving immunotherapy.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03463-8. doi: 10.1016/j.jhep.2022.
    >> Share

  398. CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
    Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
    >> Share

  399. KOERKAMP BG, Clavien PA, Polak WG
    Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?
    J Hepatol. 2022 Dec 23:S0168-8278(22)03327-X. doi: 10.1016/j.jhep.2022.
    >> Share

  400. LEE BP, Dodge JL, Terrault NA
    Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults.
    J Hepatol. 2022 Dec 22:S0168-8278(22)03460-2. doi: 10.1016/j.jhep.2022.
    >> Share

  401. HARTMANN P, Schnabl B
    Fungal infections and the fungal microbiome in hepatobiliary disorders.
    J Hepatol. 2022 Dec 21:S0168-8278(22)03415-8. doi: 10.1016/j.jhep.2022.
    >> Share

  402. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    Corrigendum to: "PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
    J Hepatol. 2022 Dec 21:S0168-8278(22)03295-0. doi: 10.1016/j.jhep.2022.
    >> Share

  403. ALBILLOS A, Krag A
    Beta-blockers in the era of precision medicine in patients with cirrhosis.
    J Hepatol. 2022 Dec 15:S0168-8278(22)03330-X. doi: 10.1016/j.jhep.2022.
    >> Share

  404. SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
    Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
    >> Share

  405. KENDRE G, Murugesan K, Brummer T, Segatto O, et al
    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.
    >> Share

  406. MAK LY, Gane E, Schwabe C, Yoon KT, et al
    A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Dec 10:S0168-8278(22)03320-7. doi: 10.1016/j.jhep.2022.
    >> Share

  407. BAIGES A, Reverter JC, Garcia Pagan JC
    Reply to "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".
    J Hepatol. 2022 Dec 9:S0168-8278(22)03322-0. doi: 10.1016/j.jhep.2022.
    >> Share

  408. LI Z, Hu Y, Li Q
    More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.
    J Hepatol. 2022 Dec 8:S0168-8278(22)03319-0. doi: 10.1016/j.jhep.2022.
    >> Share

  409. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Erratum to 'Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner' [J Hepatol 77 (2022) 1059-1070].
    J Hepatol. 2022 Dec 2:S0168-8278(22)03141-5. doi: 10.1016/j.jhep.2022.
    >> Share

  410. RUMGAY H, Arnold M, Ferlay J, Lesi O, et al
    Global burden of primary liver cancer in 2020 and predictions to 2040.
    J Hepatol. 2022;77:1598-1606.
    >> Share

  411. MITTEN EK, Baffy G
    Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:1642-1656.
    >> Share

  412. PAFILI K, Kahl S, Mastrototaro L, Strassburger K, et al
    Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
    J Hepatol. 2022;77:1504-1514.
    >> Share

  413. MENDEZ-SANCHEZ N, Pal SC
    New terms for fatty liver disease other than MAFLD: Time for a reality check.
    J Hepatol. 2022;77:1716-1717.
    >> Share

  414. BRANDEL V, Schimek V, Gober S, Hammond T, et al
    Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors.
    J Hepatol. 2022;77:1619-1630.
    >> Share

  415. TIAN C, Min X, Zhao Y, Wang Y, et al
    MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM.
    J Hepatol. 2022;77:1491-1503.
    >> Share

  416. KIM BK, Tamaki N, Imajo K, Yoneda M, et al
    Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    J Hepatol. 2022;77:1482-1490.
    >> Share

  417. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    >> Share

  418. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    >> Share

    November 2022
  419. SUN J, Ding J, Shen Q, Wang X, et al
    Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
    J Hepatol. 2022 Nov 30:S0168-8278(22)03311-6. doi: 10.1016/j.jhep.2022.
    >> Share

  420. THABUT D, Kudo M
    Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
    J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
    >> Share

  421. MIESBACH W, Foster GR, Peyvandi F
    Liver-Related Aspects of Gene Therapy for Haemophilia: Call to Action for Collaboration between Haematologists and Hepatologists.
    J Hepatol. 2022 Nov 24:S0168-8278(22)03307-4. doi: 10.1016/j.jhep.2022.
    >> Share

  422. NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
    Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
    J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
    >> Share

  423. LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
    Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
    J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
    >> Share

  424. AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
    A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
    >> Share

  425. CHOI SJ, Choi SH, Kim DW, Kwag M, et al
    Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03297-4. doi: 10.1016/j.jhep.2022.
    >> Share

  426. CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
    Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
    >> Share

  427. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    >> Share

  428. BAJAJ JS
    Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.
    >> Share

  429. SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
    Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
    >> Share

  430. CHEN S, Lu Z, Jia H, Yang B, et al
    Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
    J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
    >> Share

  431. SHEN W, Middleton MS, Cunha GM, Delgado TI, et al
    Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    J Hepatol. 2022 Nov 8. pii: S0168-8278(22)03284.
    >> Share

  432. ZHANG X, Song J, Zhang Y, Wen B, et al
    Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
    J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
    >> Share

  433. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    >> Share

  434. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
    >> Share

  435. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03162.
    >> Share

  436. VAN KLEEF LA, Kavousi M, de Knegt RJ
    Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues".
    J Hepatol. 2022;77:1467-1468.
    >> Share

  437. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
    J Hepatol. 2022;77:1454-1455.
    >> Share

  438. ENGELMANN C, Habtesion A, Hassan M, Kerbert AJ, et al
    Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
    J Hepatol. 2022;77:1325-1338.
    >> Share

  439. ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
    Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    J Hepatol. 2022;77:1237-1245.
    >> Share

  440. TRIPATHI M, Singh BK, Zhou J, Tikno K, et al
    Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
    J Hepatol. 2022;77:1246-1255.
    >> Share

  441. JIN B, Du S, Yang H
    HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
    J Hepatol. 2022;77:1469-1470.
    >> Share

  442. TSAI WC, Yu ML, Dai CY
    Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues.
    J Hepatol. 2022;77:1466-1467.
    >> Share

  443. NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
    Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    J Hepatol. 2022;77:1399-1409.
    >> Share

  444. HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
    Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
    J Hepatol. 2022;77:1373-1385.
    >> Share

  445. DIAO YK, Kong QY, Yang T
    HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
    J Hepatol. 2022;77:1468-1469.
    >> Share

  446. CHEN L, Fan Z, Lv G
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;77:1453-1454.
    >> Share

  447. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?'
    J Hepatol. 2022 Nov 1. pii: S0168-8278(22)03161.
    >> Share

    October 2022
  448. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    >> Share

  449. NOUREDDIN M, Harrison SA
    NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03159.
    >> Share

  450. CABIBBO G, Bruix J
    Radiological endpoints as surrogates for survival benefit in Hepatocellular Carcinoma trials: all that glitters is not gold.
    J Hepatol. 2022 Oct 30. pii: S0168-8278(22)03155.
    >> Share

  451. LI B, Hong C, Fan Z, Cai S, et al
    Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acutely decompensated cirrhosis.
    J Hepatol. 2022 Oct 26. pii: S0168-8278(22)03144.
    >> Share

  452. PRYKE R, Guha IN
    Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
    J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
    >> Share

  453. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    >> Share

  454. LI T, Lu Z
    Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Oct 11. pii: S0168-8278(22)03136.
    >> Share

  455. PERICAS JM, Tacke F, Anstee QM, Di Prospero NA, et al
    Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.
    J Hepatol. 2022 Oct 7. pii: S0168-8278(22)03131.
    >> Share

  456. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    >> Share

  457. BITTENCOURT PL, Oliveira CP, Codes L, Ferraz MLG, et al
    Internet search engines and social media are improving awareness on non-alcoholic fatty liver disease in Brazil.
    J Hepatol. 2022;77:1217-1219.
    >> Share

  458. PEISELER M, Schwabe R, Hampe J, Kubes P, et al
    Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    J Hepatol. 2022;77:1136-1160.
    >> Share


  459. EASL Clinical Practice Guidelines on the management of cystic liver diseases.
    J Hepatol. 2022;77:1083-1108.
    >> Share

  460. DE GOTTARDI A, Sempoux C, Berzigotti A
    Porto-sinusoidal vascular disorder.
    J Hepatol. 2022;77:1124-1135.
    >> Share

  461. VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
    Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
    J Hepatol. 2022;77:931-938.
    >> Share

  462. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:918-930.
    >> Share

  463. BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
    Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
    J Hepatol. 2022;77:1005-1013.
    >> Share

    September 2022
  464. ELFEKI MA, Singal AK
    The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
    J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
    >> Share

  465. WANG Y, Hu M, Yang H
    Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
    J Hepatol. 2022 Sep 27. pii: S0168-8278(22)03122.
    >> Share

  466. REINIS J, Petrenko O, Simbrunner B, Hofer BS, et al
    Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03119.
    >> Share

  467. FAGAN A, Gavis EA, Gallagher ML, Mousel T, et al
    A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03116.
    >> Share

  468. RIDOLA L, Riggio O
    Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
    >> Share

  469. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    >> Share

  470. ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
    Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
    >> Share

  471. KUDO M, Finn RS, Qin S, Han KH, et al
    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03111.
    >> Share

  472. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    >> Share

  473. MAIWALL R, Deshmukh A, Sarin SK
    Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
    J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
    >> Share

  474. PARIKH ND, Tayob N, Singal AG
    Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
    J Hepatol. 2022 Sep 8. pii: S0168-8278(22)03067.
    >> Share

  475. KAZANKOV K, Novelli S, Chatterjee DA, Phillips A, et al
    Evaluation of CirrhoCare(R) - A digital-health solution for home management of patients with cirrhosis.
    J Hepatol. 2022 Sep 7. pii: S0168-8278(22)03066.
    >> Share

  476. PATERNOSTRO R, Kwanten WJ, Reiberger T
    Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
    >> Share

  477. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    >> Share

  478. LUJAMBIO A, Sarobe P
    Metformin keeps CD8(+) T cells active and moving in NASH-HCC immunotherapy.
    J Hepatol. 2022;77:593-595.
    >> Share

  479. MANDORFER M, Scheiner B, Lisman T
    On coagulation in advanced chronic liver disease and the origin of freshwater eels.
    J Hepatol. 2022;77:886-887.
    >> Share

  480. LANGER MM, Eickelmann C, Kleinbongard P, Lange CM, et al
    Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensation.
    J Hepatol. 2022;77:874-876.
    >> Share

  481. CHEN ZX, Liu SY, Tong XM
    Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
    J Hepatol. 2022;77:892-893.
    >> Share

  482. GREUTER T, Yaqoob U, Gan C, Jalan-Sakrikar N, et al
    Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.
    J Hepatol. 2022;77:723-734.
    >> Share

  483. CHOI SE, Hwang Y, Lee SJ, Jung H, et al
    Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice.
    J Hepatol. 2022;77:735-747.
    >> Share

  484. BASELLI GA, Jamialahmadi O, Pelusi S, Ciociola E, et al
    Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
    J Hepatol. 2022;77:596-606.
    >> Share

  485. WABITSCH S, McCallen JD, Kamenyeva O, Ruf B, et al
    Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.
    J Hepatol. 2022;77:748-760.
    >> Share

  486. XIE J, Lu L, Chen Y, Xu L, et al
    A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults.
    J Hepatol. 2022;77:877-879.
    >> Share

  487. BAIGES A, Procopet B, Silva-Junior G, Llop E, et al
    Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03054.
    >> Share

  488. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    >> Share

    August 2022
  489. WHITFIELD JB, Morgan TR, Seth D
    Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Aug 30. pii: S0168-8278(22)03055.
    >> Share

  490. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    >> Share

  491. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    >> Share

  492. SALEM R, Greten TF
    Interventional radiology meets immuno-oncology for hepatocellular carcinoma.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03003.
    >> Share

  493. LABENZ C, Arslanow A, Lammert F, Galle PR, et al
    Reply to: "an individualized cirrhosis screening strategy might be more cost-effective in the general population".
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03006.
    >> Share

  494. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    >> Share

  495. BASELLI G, Romeo S, Valenti L
    Reply to: "Lack of hepatic autophagy promotes severity of liver injury but not steatosis": ATG7 genetic variants behave as fatty liver disease progression modifiers.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02992.
    >> Share

  496. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    >> Share

  497. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    >> Share

  498. JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
    Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
    >> Share

  499. BAILEY AL, Diamond MS
    Hepatopathology of flaviviruses.
    J Hepatol. 2022 Aug 15. pii: S0168-8278(22)00339.
    >> Share

  500. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    >> Share

  501. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    >> Share

  502. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    >> Share

  503. GEHRING AJ, MacParland SA
    Intrahepatic T cells with NK-like properties: expanding the repertoire of lymphocytes sensitive to bystander activation.
    J Hepatol. 2022 Aug 12. pii: S0168-8278(22)02985.
    >> Share

  504. ALAZAWI W
    Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
    J Hepatol. 2022;77:290-292.
    >> Share


  505. EASL Clinical Practice Guidelines on haemochromatosis.
    J Hepatol. 2022;77:479-502.
    >> Share

  506. SCHOMERUS G, Leonhard A, Manthey J, Morris J, et al
    The stigma of alcohol-related liver disease and its impact on healthcare.
    J Hepatol. 2022;77:516-524.
    >> Share

  507. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    >> Share

  508. BUGIANESI E, Petta S
    NAFLD/NASH.
    J Hepatol. 2022;77:549-550.
    >> Share

  509. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    >> Share

  510. ROWE IA, D'Amico G
    Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.
    J Hepatol. 2022;77:293-295.
    >> Share

  511. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    >> Share

  512. ABERG F, Luukkonen PK, But A, Salomaa V, et al
    Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
    J Hepatol. 2022;77:302-311.
    >> Share

  513. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    >> Share

    July 2022
  514. TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
    Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
    >> Share

  515. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    >> Share

  516. NELL P, Kattler K, Feuerborn D, Hellwig B, et al
    Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02943.
    >> Share

  517. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    >> Share

  518. ZHAO S, Liao X, Fan R
    An individualized cirrhosis screening strategy might be more cost-effective in the general population.
    J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
    >> Share

  519. MAIMONE S, Tripodi VF, Mazzeo AT
    Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
    >> Share

  520. FONTANELLAS A, Avila MA
    Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02921.
    >> Share

  521. BARCENA-VARELA M
    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.
    >> Share

  522. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.
    >> Share

  523. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    >> Share

  524. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    >> Share

  525. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.
    >> Share

  526. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.
    >> Share

    June 2022
  527. VERMA AK, Sharma A, Subramaniyam N, Gandhi CR, et al
    Augmenter of liver regeneration: mitochondrial function and steatohepatitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00413.
    >> Share

  528. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    >> Share

  529. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    >> Share

  530. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    >> Share

  531. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    >> Share

  532. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
    >> Share

  533. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    >> Share

  534. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    >> Share

  535. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    >> Share

  536. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    >> Share

  537. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
    >> Share

  538. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    >> Share


  539. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
    >> Share

  540. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    >> Share

  541. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    >> Share

  542. CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
    Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
    J Hepatol. 2022;76:1348-1361.
    >> Share

  543. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    >> Share

  544. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    >> Share

  545. TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
    Breakthroughs in hepatology.
    J Hepatol. 2022;76:1247-1248.
    >> Share

  546. GARDIN A, Remih K, Gonzales E, Andersson ER, et al
    Modern therapeutic approaches to liver-related disorders.
    J Hepatol. 2022;76:1392-1409.
    >> Share

  547. BAJAJ JS, Ng SC, Schnabl B
    Promises of microbiome-based therapies.
    J Hepatol. 2022;76:1379-1391.
    >> Share

  548. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    >> Share

  549. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    >> Share

    May 2022
  550. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    >> Share

  551. MOLINA L, Zhu J, Trepo E, Bayard Q, et al
    Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
    >> Share

  552. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
    >> Share

  553. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    >> Share

  554. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    >> Share

  555. DING WX, Ni HM, Waguri S, Komatsu M, et al
    Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
    >> Share

  556. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    >> Share

  557. HUSAIN A, Chiu YT, Oi-Lin Ng I
    EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
    >> Share

  558. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    >> Share

  559. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    >> Share

  560. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    >> Share

  561. SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
    Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
    >> Share

  562. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    >> Share

  563. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    >> Share

  564. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
    >> Share

  565. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
    >> Share

  566. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    >> Share

  567. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    >> Share

  568. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
    >> Share

  569. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
    J Hepatol. 2022;76:995-1000.
    >> Share

  570. REIG M, Bruix J
    Reply to: "Correspondence on the ".
    J Hepatol. 2022;76:1240-1241.
    >> Share

  571. PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;76:1021-1029.
    >> Share

  572. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    >> Share

  573. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    >> Share

  574. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    >> Share

  575. XU X, Lau WY, Yang T
    The updated BCLC staging system needs further refinement: A surgeon's perspective.
    J Hepatol. 2022;76:1239-1240.
    >> Share

  576. MARJOT T, Ray DW, Tomlinson JW
    Is it time for chronopharmacology in NASH?
    J Hepatol. 2022;76:1215-1224.
    >> Share

  577. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    >> Share

  578. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    >> Share

  579. BERRY P, Kotha S
    Improving end of life care in liver disease.
    J Hepatol. 2022;76:1225-1226.
    >> Share

  580. ELHENCE A, Shalimar
    Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
    J Hepatol. 2022;76:1236-1237.
    >> Share

  581. GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
    Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:1001-1012.
    >> Share

    April 2022
  582. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    >> Share

  583. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    >> Share

  584. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    >> Share

  585. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    >> Share

  586. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    >> Share

  587. ZHANGYUAN G
    Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
    >> Share

  588. JIANG X, Fulte S, Deng F, Chen S, et al
    Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
    >> Share

  589. ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
    Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
    >> Share

  590. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
    >> Share

  591. CHUAH S, Lee J, Song Y, Kim HD, et al
    Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
    >> Share

  592. LI C, Ouyang W, Yang T
    The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
    >> Share

  593. CHAPIRO J
    Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
    >> Share

  594. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    >> Share

  595. RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
    HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
    >> Share

  596. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
    >> Share

  597. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
    >> Share

  598. DEMIR M, Lang S, Hartmann P, Duan Y, et al
    The fecal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:788-799.
    >> Share

  599. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    >> Share

  600. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    >> Share

  601. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    >> Share

  602. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    >> Share

  603. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    >> Share

  604. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    >> Share

  605. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    >> Share

    March 2022
  606. BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
    T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
    >> Share

  607. WANG S, Wu Q, Chen T, Su R, et al
    Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
    >> Share

  608. LI D, Yi C, Huang H, Li J, et al
    Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
    >> Share

  609. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    >> Share

  610. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    >> Share

  611. JALAN R, Rose CF
    Heretical thoughts into Hepatic Encephalopathy.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
    >> Share

  612. BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
    Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
    >> Share

  613. LIN P, Yang H
    EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
    >> Share

  614. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    >> Share

  615. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    >> Share

  616. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    >> Share

  617. YANG Y, Ouyang J, Zhou Y, Zhou J, et al
    The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
    >> Share

  618. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    >> Share

  619. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    >> Share

  620. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    >> Share

  621. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    >> Share

  622. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    >> Share

  623. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    >> Share

  624. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    >> Share

  625. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    >> Share

  626. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    >> Share

  627. SUN X, Wu J, Liu L, Chen Y, et al
    Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
    J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
    >> Share

  628. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    >> Share

  629. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    >> Share

  630. LOESCH R, Caruso S, Paradis V, Godard C, et al
    Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
    J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
    >> Share


  631. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    >> Share

  632. SPELIOTES EK, George J
    Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    J Hepatol. 2022;76:498-500.
    >> Share

  633. DING WX, Sancho-Bru P
    SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
    J Hepatol. 2022;76:503-505.
    >> Share

  634. MARTINEZ J, Hernandez-Gea V, Albillos A
    Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
    J Hepatol. 2022;76:752-753.
    >> Share

  635. SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
    Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;76:739-740.
    >> Share

  636. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    >> Share

  637. EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
    The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
    J Hepatol. 2022;76:738-739.
    >> Share

  638. LIU D, Zhang Q, Bai P, Zhao J, et al
    Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:740-742.
    >> Share

  639. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    >> Share

  640. ALABSAWY E, Shalimar, Jalan R
    Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
    J Hepatol. 2022;76:751-752.
    >> Share


  641. Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
    J Hepatol. 2022;76:758.
    >> Share

  642. GUO B, Guo Y, Nima Q, Feng Y, et al
    Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2022;76:518-525.
    >> Share

  643. REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
    BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
    J Hepatol. 2022;76:681-693.
    >> Share

  644. KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
    Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
    J Hepatol. 2022;76:665-680.
    >> Share

  645. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    >> Share

  646. RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
    EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    J Hepatol. 2022;76:506-517.
    >> Share

  647. LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
    Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:526-535.
    >> Share

  648. YIP TC, Lee HW, Chan WK, Wong GL, et al
    Asian perspective on NAFLD-associated HCC.
    J Hepatol. 2022;76:726-734.
    >> Share

    February 2022
  649. HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
    Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
    J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
    >> Share

  650. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
    >> Share

  651. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
    >> Share

  652. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    >> Share

  653. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    >> Share

  654. OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
    Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
    J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
    >> Share

  655. SCHEINER B, Pinter M
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
    J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
    >> Share

  656. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    >> Share

  657. JEONG J, Tanaka M, Iwakiri Y
    Hepatic lymphatic vascular system in health and disease.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
    >> Share

  658. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    >> Share

  659. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
    >> Share

  660. ZINGONI A, Banales JM
    PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
    J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
    >> Share

  661. ZENG Q, Klein C, Caruso S, Maille P, et al
    Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
    >> Share

  662. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    >> Share

  663. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    >> Share

  664. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    >> Share

  665. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    >> Share

  666. KIM D, Ahmed A
    Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
    J Hepatol. 2022;76:477-478.
    >> Share

  667. FOUAD YM, Mendez-Sanchez N, Zheng MH
    One not like the other: The weakness of the blood sugar-MAFLD analogy.
    J Hepatol. 2022;76:482-484.
    >> Share

  668. DE A, Ahmad N, Mehta M, Singh P, et al
    NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
    J Hepatol. 2022;76:475-477.
    >> Share

  669. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    >> Share

  670. WANG YZ
    MAFLD supported by 95.45% participants of CSH is NOT representative.
    J Hepatol. 2022;76:481-482.
    >> Share

  671. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    >> Share

  672. DANA J, Debray D, Beaufrere A, Hillaire S, et al
    Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    J Hepatol. 2022;76:420-434.
    >> Share

  673. MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
    Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
    J Hepatol. 2022;76:265-274.
    >> Share

  674. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    >> Share

    January 2022
  675. YANG M, Wu X, Hu J, Wang Y, et al
    COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
    >> Share

  676. BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
    Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
    >> Share

  677. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    >> Share

  678. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    >> Share

  679. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    >> Share

  680. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    >> Share

  681. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    >> Share

  682. ZHOU HF, Yang W, Zhou WZ
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
    J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
    >> Share

  683. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    >> Share

  684. CRAMER T, Vaupel P
    Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
    >> Share

  685. JAGADISAN B, Dhawan A
    Emergencies in Pediatric hepatology.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
    >> Share

  686. MALLET V, Schwarzinger M
    Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
    J Hepatol. 2022;76:229-230.
    >> Share

  687. LONG J, Sang X, Zhao H
    Association of chronic liver disease with the prognosis of COVID-19 patients.
    J Hepatol. 2022;76:228-229.
    >> Share

  688. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    >> Share

  689. SCHUPPAN D, Myneni S, Surabattula R
    Liquid biomarkers for fibrotic NASH - progress in a complex field.
    J Hepatol. 2022;76:5-7.
    >> Share


  690. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
    J Hepatol. 2022;76:251-252.
    >> Share

  691. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    >> Share

  692. TURON F, Lisman T, Carlos-Garcia-Pagan J
    Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
    J Hepatol. 2022;76:227-228.
    >> Share

  693. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    >> Share

  694. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    >> Share

  695. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    >> Share

  696. LIU Y, Liu C, Li J, Kim TH, et al
    Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
    J Hepatol. 2022;76:248-250.
    >> Share

  697. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    >> Share

  698. DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
    J Hepatol. 2022;76:11-24.
    >> Share

  699. VOGEL A, Saborowski A
    Medical therapy of HCC.
    J Hepatol. 2022;76:208-210.
    >> Share

  700. LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
    An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
    J Hepatol. 2022;76:247-248.
    >> Share

  701. SINGAL AG, El-Serag HB
    Rational HCC screening approaches for patients with NAFLD.
    J Hepatol. 2022;76:195-201.
    >> Share

  702. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    >> Share

  703. SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
    HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    J Hepatol. 2022;76:53-62.
    >> Share

  704. ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
    Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
    J Hepatol. 2022;76:93-106.
    >> Share

  705. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    >> Share

    December 2021
  706. SCHEINER B, Pinter M
    Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
    J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
    >> Share

  707. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    >> Share

  708. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    >> Share

  709. WANG H, Zhang S, Zhang Y, Jia J, et al
    Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
    >> Share

  710. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    >> Share

  711. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    >> Share

  712. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    >> Share

  713. TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
    Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
    J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
    >> Share

  714. WANG X, Zeldin S, Shi H, Zhu C, et al
    TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
    >> Share

  715. CHENG AL, Qin S, Ikeda M, Galle PR, et al
    Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
    >> Share

  716. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    >> Share

  717. KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
    Michael Charles Kew - Frontrunner in Hepatology.
    J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
    >> Share

  718. KADONO K, Kageyama S, Nakamura K, Hirao H, et al
    Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
    >> Share

  719. NACHIT M, Kwanten WJ, Francque S
    Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
    J Hepatol. 2021;75:1513-1514.
    >> Share

  720. LUEDDE T, Baumann U, Keitel V
    Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
    J Hepatol. 2021;75:1502-1503.
    >> Share

  721. WONG VW, Lazarus JV
    Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    J Hepatol. 2021;75:1267-1270.
    >> Share

  722. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    >> Share

  723. MATTHEWS C, Cross TJS
    Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
    J Hepatol. 2021;75:1494-1495.
    >> Share

  724. KOTHA S, Berry P
    Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
    J Hepatol. 2021;75:1501-1502.
    >> Share

  725. CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
    Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
    J Hepatol. 2021;75:1511-1513.
    >> Share

  726. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    >> Share

  727. IOANNOU GN
    Epidemiology and risk-stratification of NAFLD-associated HCC.
    J Hepatol. 2021;75:1476-1484.
    >> Share

  728. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    >> Share

  729. HSU CL, Duan Y, Fouts DE, Schnabl B, et al
    Intestinal virome and therapeutic potential of bacteriophages in liver disease.
    J Hepatol. 2021;75:1465-1475.
    >> Share

  730. KIM D, Konyn P, Sandhu KK, Dennis BB, et al
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021;75:1284-1291.
    >> Share

  731. ENGELMANN C, Herber A, Franke A, Bruns T, et al
    Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
    J Hepatol. 2021;75:1346-1354.
    >> Share

  732. GADALETA RM, Moschetta A
    Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
    J Hepatol. 2021;75:1440-1451.
    >> Share

  733. D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
    Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
    J Hepatol. 2021;75:1355-1366.
    >> Share

    November 2021
  734. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    >> Share

  735. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    >> Share

  736. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    >> Share

  737. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    >> Share

  738. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    >> Share

  739. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    >> Share

  740. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    >> Share

  741. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    >> Share

  742. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    >> Share

  743. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    >> Share

  744. COLOMBO M, Barouki R
    Expanding the liver exposome: should hepatologists care about air pollution?
    J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
    >> Share

  745. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    >> Share

  746. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    >> Share

  747. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    >> Share

  748. GUPTA P, Sharma V, Kalra N
    Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
    J Hepatol. 2021;75:1259-1260.
    >> Share

  749. VILLANUEVA C, Bosch J
    Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
    J Hepatol. 2021;75:1242-1243.
    >> Share

  750. KUTAIBA N, Ardalan Z
    Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
    J Hepatol. 2021;75:1258-1259.
    >> Share

  751. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    >> Share

  752. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    >> Share

  753. REICHERT MC, Ripoll C
    First things first! Can bacterial infections be considered as decompensating events per se?
    J Hepatol. 2021;75:1241-1242.
    >> Share

  754. LANGE NF, Radu P, Dufour JF
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021;75:1217-1227.
    >> Share

  755. HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
    Maternal obesity increases the risk and severity of NAFLD in offspring.
    J Hepatol. 2021;75:1042-1048.
    >> Share

  756. RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
    The multifaceted role of cathepsins in liver disease.
    J Hepatol. 2021;75:1192-1202.
    >> Share

  757. SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
    Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    J Hepatol. 2021;75:1034-1041.
    >> Share

  758. WANG Q, Liang N, Yang T, Li Y, et al
    DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
    J Hepatol. 2021;75:1142-1153.
    >> Share

  759. JALAN R, Gustot T, Fernandez J, Bernal W, et al
    'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
    J Hepatol. 2021;75:1228-1235.
    >> Share

  760. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    >> Share

  761. RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
    Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
    J Hepatol. 2021;75:1017-1025.
    >> Share

  762. LI F, Thuluvath PJ
    EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
    J Hepatol. 2021;75:1096-1103.
    >> Share

    October 2021
  763. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    >> Share

  764. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    >> Share

  765. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    >> Share

  766. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    >> Share

  767. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    >> Share

  768. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    >> Share

  769. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    >> Share

  770. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    >> Share

  771. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    >> Share

  772. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    >> Share

  773. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    >> Share

  774. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    >> Share

  775. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    >> Share

  776. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    >> Share

  777. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    >> Share

  778. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    >> Share

  779. CHEN X, Chen S, Pang J, Tang Y, et al
    Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
    J Hepatol. 2021;75:987-989.
    >> Share

  780. LACKNER C, Stauber RE, Davies S, Denk H, et al
    Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
    J Hepatol. 2021;75:810-819.
    >> Share

  781. YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
    Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:786-794.
    >> Share

  782. GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
    Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    J Hepatol. 2021;75:795-809.
    >> Share

  783. SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
    Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    J Hepatol. 2021;75:770-785.
    >> Share

    September 2021
  784. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    >> Share

  785. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    >> Share

  786. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    >> Share

  787. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    >> Share

  788. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    >> Share

  789. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    >> Share

  790. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    >> Share

  791. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    >> Share

  792. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    >> Share

  793. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    >> Share

  794. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    >> Share

  795. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    >> Share

  796. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    >> Share

  797. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    >> Share

  798. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    >> Share

  799. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    >> Share

  800. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    >> Share

  801. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    >> Share

  802. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    >> Share

  803. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    >> Share

  804. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    >> Share

  805. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    >> Share

  806. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    >> Share


  807. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
    J Hepatol. 2021;75:659-689.
    >> Share

  808. YOO T, Joo SK, Kim HJ, Kim HY, et al
    Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:514-523.
    >> Share

  809. CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
    Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
    J Hepatol. 2021;75:506-513.
    >> Share

    August 2021
  810. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    >> Share

  811. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    >> Share

  812. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    >> Share

  813. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    >> Share

  814. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    >> Share

  815. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    >> Share

  816. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    >> Share

  817. NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    J Hepatol. 2021;75:292-301.
    >> Share

  818. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    >> Share

  819. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    >> Share

  820. MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
    Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
    J Hepatol. 2021;75:342-350.
    >> Share

  821. YANG Y, Sangwung P, Kondo R, Jung Y, et al
    Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    J Hepatol. 2021;75:377-386.
    >> Share

    July 2021
  822. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    >> Share

  823. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    >> Share

  824. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    >> Share

  825. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    >> Share

  826. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    >> Share

  827. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    >> Share

  828. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    >> Share

  829. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    >> Share

  830. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    >> Share

  831. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    >> Share

  832. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    >> Share

  833. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    >> Share

  834. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    >> Share

  835. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    >> Share

  836. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    >> Share

  837. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    >> Share

  838. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    >> Share

  839. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    >> Share

  840. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    >> Share

  841. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    >> Share

  842. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    >> Share

  843. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    >> Share

  844. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    >> Share

  845. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    >> Share

  846. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    >> Share

  847. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    >> Share

  848. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    >> Share

  849. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    >> Share

  850. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    >> Share

  851. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    >> Share

  852. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    >> Share

  853. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    >> Share

  854. BEUERS U
    EASL recognition award recipient 2021: Prof. Dieter Haussinger.
    J Hepatol. 2021;75:7-9.
    >> Share

  855. ROMERO-GOMEZ M
    EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
    J Hepatol. 2021;75:10-11.
    >> Share

  856. MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
    Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
    J Hepatol. 2021;75:221-222.
    >> Share

  857. PETERS L, Burkert S, Gruner B
    Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
    J Hepatol. 2021;75:202-218.
    >> Share

  858. SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
    Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
    J Hepatol. 2021;75:34-45.
    >> Share

  859. LIU C, Zhou B, Meng M, Zhao W, et al
    FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:150-162.
    >> Share

  860. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    >> Share